Another retrospective multicenter cohort study encompassing 538 patients with an EGFR mutation who received osimertinib as initial therapy17 reported that PFS for malignant effusion, which included pericardial effusion and pleural/ascites effusion, was low (HR 1.51; 95% CI: 1.11–2.04). The gene discussed is EGFR; the disease is pericardial effusion.